All Stories

  1. Adaptive motility enables neutrophils to rapidly navigate confined capillaries
  2. No Effect of Ppm1d -Mutant Clonal Hematopoiesis on Atherosclerosis Development in Mice
  3. Reaching for the cure as progeria research comes of age at the 12th international scientific workshop
  4. Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period
  5. Lipid-laden macrophages in atherosclerosis and cancer
  6. Lamin A/C Expression in Hematopoietic Cells Declines During Human Aging and Constrains Atherosclerosis in Mice
  7. Vascular cell types in progeria: victims or villains?
  8. Roadmap for alleviating the manifestations of ageing in the cardiovascular system
  9. Endothelial-to-Mesenchymal Transition Contributes to Accelerated Atherosclerosis in Hutchinson-Gilford Progeria Syndrome
  10. Endothelial cell‐specific progerin expression does not cause cardiovascular alterations and premature death
  11. Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome
  12. Influence of Subclinical Atherosclerosis Burden and Progression on Mortality
  13. Unidirectional association of clonal hematopoiesis with atherosclerosis development
  14. β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia–reperfusion injury
  15. Identified the key target cell type for strategies to prevent atherosclerosis in progeria
  16. RhoA/rho kinase pathway activation in age‐associated endothelial cell dysfunction and thrombosis
  17. Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation
  18. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years
  19. Aging and Vascular Disease: A Multidisciplinary Overview
  20. Lamin A/C Ablation Restricted to Vascular Smooth Muscle Cells, Cardiomyocytes, and Cardiac Fibroblasts Causes Cardiac and Vascular Dysfunction
  21. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study
  22. Lamin A/C Ablation in Vascular Smooth Muscle Cells, Cardiomyocytes, and Cardiac Fibroblasts Causes Cardiac and Vascular Dysfunction: Role in the Pathophysiology of LMNA-Related Dilated Cardiomyopathies
  23. Coronary and carotid artery dysfunction and KV7 overexpression in a mouse model of Hutchinson-Gilford progeria syndrome
  24. Emerging roles of interferon-stimulated gene-15 in age-related telomere attrition, the DNA damage response, and cardiovascular disease
  25. Analysis of Monocyte Recruitment During Inflammation by Intravital Imaging
  26. Kir2.1 dysfunction at the sarcolemma and the sarcoplasmic reticulum causes arrhythmias in a mouse model of Andersen–Tawil syndrome type 1
  27. Quantification of Farnesylated Progerin in Hutchinson-Gilford Progeria Patient Cells by Mass Spectrometry
  28. Failing Hypertensive Heart: a Question of Altered Telomere Biology?
  29. Polypill Strategy in Secondary Cardiovascular Prevention
  30. Status of treatment strategies for Hutchinson–Gilford progeria syndrome with a focus on prelamin: A posttranslational modification
  31. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome
  32. Progeria: a perspective on potential drug targets and treatment strategies
  33. Bone marrow activation in response to metabolic syndrome and early atherosclerosis
  34. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome
  35. Targeting Tyrosine Hydroxylase for Abdominal Aortic Aneurysm: Impact on Inflammation, Oxidative Stress, and Vascular Remodeling
  36. Genomic instability in the naturally and prematurely aged myocardium
  37. Progression of Early Subclinical Atherosclerosis (PESA) Study
  38. Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson–Gilford Progeria Syndrome
  39. Triglycerides and Residual Atherosclerotic Risk
  40. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models
  41. The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives – webinar version scientific summary
  42. Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA
  43. Telomerase as a Therapeutic Target in Cardiovascular Disease
  44. Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson–Gilford progeria syndrome
  45. Premature Vascular Aging with Features of Plaque Vulnerability in an Atheroprone Mouse Model of Hutchinson–Gilford Progeria Syndrome with Ldlr Deficiency
  46. Machine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individuals
  47. Deletion or Inhibition of NOD1 Favors Plaque Stability and Attenuates Atherothrombosis in Advanced Atherogenesis
  48. Identification of common cardiometabolic alterations and deregulated pathways in mouse and pig models of aging
  49. The pharmaceutical solvent N-methyl-2-pyrollidone (NMP) attenuates inflammation through Krüppel-like factor 2 activation to reduce atherogenesis
  50. Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
  51. miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis
  52. Short-Term Progression of Multiterritorial Subclinical Atherosclerosis
  53. Vascular Smooth Muscle Cell-Specific Progerin Expression Provokes Contractile Impairment in a Mouse Model of Hutchinson-Gilford Progeria Syndrome that Is Ameliorated by Nitrite Treatment
  54. Biological Versus Chronological Aging
  55. Endothelial MT 1‐ MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis
  56. Lamin A/C deficiency in CD4+ T‐cells enhances regulatory T‐cells and prevents inflammatory bowel disease
  57. Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging
  58. Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice
  59. Generation and characterization of a novel knockin minipig model of Hutchinson-Gilford progeria syndrome
  60. Vascular smooth muscle cell‐specific progerin expression in a mouse model of Hutchinson–Gilford progeria syndrome promotes arterial stiffness: Therapeutic effect of dietary nitrite
  61. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells
  62. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome
  63. Endothelial NOD1 directs myeloid cell recruitment in atherosclerosis through VCAM‐1
  64. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification
  65. The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function
  66. Accelerated atherosclerosis in HGPS
  67. Electrocardiographic Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome
  68. Telomere Length as Cardiovascular Aging Biomarker
  69. Vascular Smooth Muscle–Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome
  70. miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis
  71. MT4-MMP deficiency increases patrolling monocyte recruitment to early lesions and accelerates atherosclerosis
  72. Mecanismos de envejecimiento vascular: ¿Qué podemos aprender del síndrome de progeria de Hutchinson-Gilford?
  73. Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation
  74. Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome
  75. Lamin A/C augments Th1 differentiation and response against vaccinia virus and Leishmania major
  76. Current State of Basic and Translational Cardiovascular Research in Spain
  77. A-type lamins and cardiovascular disease in premature aging syndromes
  78. Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate
  79. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
  80. Proteomics Research in Cardiovascular Medicine and Biomarker Discovery
  81. Cardiac electrical defects in progeroid mice and Hutchinson–Gilford progeria syndrome patients with nuclear lamina alterations
  82. The CNIC
  83. Nestin+ cells direct inflammatory cell migration in atherosclerosis
  84. Endothelial Jag1-RBPJ signalling promotes inflammatory leucocyte recruitment and atherosclerosis
  85. Alternatively activated macrophages exhibit an anticalcifying activity dependent on extracellular ATP/pyrophosphate metabolism
  86. A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics
  87. Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis
  88. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression
  89. Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling
  90. Loss of p27 phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte recruitment via RhoA/ROCK
  91. Impact of estrogens on atherosclerosis and bone in the apolipoprotein E–deficient mouse model
  92. Targeting γ-secretases protect against angiotensin II-induced cardiac hypertrophy
  93. ADAMTS7 in Cardiovascular Disease
  94. In Vitro Macrophage Phagocytosis Assay
  95. Isolation of Mouse Primary Aortic Endothelial Cells by Selection with Specific Antibodies
  96. Oil Red O and Hematoxylin and Eosin Staining for Quantification of Atherosclerosis Burden in Mouse Aorta and Aortic Root
  97. Sorting Nexin 6 Enhances Lamin A Synthesis and Incorporation into the Nuclear Envelope
  98. Vitamin D puts the brakes on angiotensin II-induced oxidative stress and vascular smooth muscle cell senescence
  99. Nuclear Envelope Lamin-A Couples Actin Dynamics with Immunological Synapse Architecture and T Cell Activation
  100. Polμ Deficiency Increases Resistance to Oxidative Damage and Delays Liver Aging
  101. High-Resolution Imaging of Intravascular Atherogenic Inflammation in Live Mice
  102. Age-dependent defective TGF-beta1 signaling in patients undergoing coronary artery bypass grafting
  103. Genetic Variants in CCNB1 Associated With Differential Gene Transcription and Risk of Coronary In-Stent Restenosis
  104. A major role for RCAN1 in atherosclerosis progression
  105. Identification of mitochondrial dysfunction in Hutchinson–Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture
  106. PI3K p110γ Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions
  107. Snake venomics of Lachesis muta rhombeata and genus-wide antivenomics assessment of the paraspecific immunoreactivity of two antivenoms evidence the high compositional and immunological conservation across Lachesis
  108. Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilford Progeria Syndrome That Is Ameliorated on Pyrophosphate Treatment
  109. Aryl hydrocarbon receptor contributes to the MEK/ERK-dependent maintenance of the immature state of human dendritic cells
  110. Embryological-Origin-Dependent Differences in Homeobox Expression in Adult Aorta: Role in Regional Phenotypic Variability and Regulation of NF- B Activity
  111. Inactivation of Nuclear Factor-Y Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation
  112. Role of c-MYC in tumor-associated macrophages and cancer progression
  113. Increased dosage ofInk4/Arfprotects against glucose intolerance and insulin resistance associated with aging
  114. Macrophage proliferation and apoptosis in atherosclerosis
  115. In Vivo Inhibition of c-MYC in Myeloid Cells Impairs Tumor-Associated Macrophage Maturation and Pro-Tumoral Activities
  116. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis
  117. Limus Is Not Limus—A Proposal to Adjust Terminology in the Context of Drug-eluting Stents
  118. Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice
  119. The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells
  120. Animal Models of Atherosclerosis
  121. Synthesis, transport and incorporation into the nuclear envelope of A-type lamins and inner nuclear membrane proteins
  122. A glimpse on the phenomenon of macrophage polarization during atherosclerosis
  123. Splicing-Directed Therapy in a New Mouse Model of Human Accelerated Aging
  124. Deficient p27 Phosphorylation at Serine 10 Increases Macrophage Foam Cell Formation and Aggravates Atherosclerosis Through a Proliferation-Independent Mechanism
  125. Insulin Receptor Substrate-1 Expression Is Increased in Circulating Leukocytes of Patients with Acute Coronary Syndrome
  126. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy
  127. Hutchinson-Gilford progeria syndrome, cardiovascular disease and oxidative stress
  128. ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-independent disruption of retinoblastoma–lamin A complexes
  129. A role for miR-33 in p53 regulation: New perspectives for hematopoietic stem cell research
  130. Tumor suppressor p27Kip1 undergoes endolysosomal degradation through its interaction with sorting nexin 6
  131. p19ARFDeficiency Reduces Macrophage and Vascular Smooth Muscle Cell Apoptosis and Aggravates Atherosclerosis
  132. Role of A-type lamins in signaling, transcription, and chromatin organization
  133. Control of cell proliferation in atherosclerosis: insights from animal models and human studies
  134. Molecular Mechanisms of Atherosclerosis in Metabolic Syndrome
  135. Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope
  136. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69
  137. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation
  138. Telomere dysfunction in hypertension
  139. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis
  140. Classic and novel roles of p53: prospects for anticancer therapy
  141. Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 Genes in the Risk of Atherosclerosis and Myocardial Infarction
  142. Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis
  143. Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice
  144. Telomere Biology and Cardiovascular Disease
  145. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients
  146. Cytostatic gene therapy for occlusive vascular disease
  147. A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C
  148. Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN
  149. Atheroma development in apolipoprotein E‐null mice is not regulated by phosphorylation of p27Kip1 on threonine 187
  150. Aging, telomeres, and atherosclerosis
  151. Transcriptional profiling of early onset diet-induced atherosclerosis in apolipoprotein E-deficient mice
  152. Unexpected Proatherogenic Properties of p21
  153. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential
  154. Atherogenic role of the type EIIIA fibronectin domain
  155. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression
  156. Telomeres and Cardiovascular Disease
  157. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway
  158. Selective inactivation of p27Kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis
  159. Short telomeres protect from diet‐induced atherosclerosis in apolipoprotein E‐null mice
  160. Optic Nerve Alterations in Apolipoprotein E Deficient Mice
  161. Cyclin-dependent protein kinases as therapeutic targets in cardiovascular disease
  162. Coordinate Control of Proliferation and Migration by the p27 Kip1 /Cyclin-Dependent Kinase/Retinoblastoma Pathway in Vascular Smooth Muscle Cells and Fibroblasts
  163. Role of the Growth Suppressor p27Kip1 During Vascular Remodeling
  164. Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
  165. Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
  166. Distinct Regulation of Mitogen-activated Protein Kinases and p27Kip1 in Smooth Muscle Cells from Different Vascular Beds
  167. Increased early atherogenesis in young versus old hypercholesterolemic rabbits by a mechanism independent of arterial cell proliferation
  168. The growth suppressor p27Kip1 protects against diet-induced atherosclerosis
  169. Overexpression of p27Kip1by doxycycline‐regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis
  170. Inhibition of the cyclin D1/E2F pathway by PCA‐4230, a potent repressor of cellular proliferation
  171. Role of Sp1 in the Induction of p27 Gene Expression in Vascular Smooth Muscle Cells In Vitro and After Balloon Angioplasty
  172. Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
  173. Age-dependent increase in c-fos activity and cyclin A expression in vascular smooth muscle cells A potential link between aging, smooth muscle cell proliferation and atherosclerosis
  174. Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease
  175. Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21Cip1/WAF1
  176. Antibody Blockade of Thrombospondin Accelerates Reendothelialization and Reduces Neointima Formation in Balloon-Injured Rat Carotid Artery
  177. Differential regulation of the retinoblastoma family of proteins during cell proliferation and differentiation
  178. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (review).
  179. Nitric Oxide–Induced Downregulation of Cdk2 Activity and Cyclin A Gene Transcription in Vascular Smooth Muscle Cells
  180. Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation.
  181. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.
  182. Histopathology of In-Stent Restenosis in Patients With Peripheral Artery Disease
  183. Embryonic Expression of the Gax Homeodomain Protein in Cardiac, Smooth, and Skeletal Muscle
  184. Myofibril-bound muscle phosphofructokinase is less sensitive to inhibition by ATP than the free enzyme, but retains its sensitivity to stimulation by bisphosphorylated hexoses
  185. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis.
  186. Determination of the Consensus Binding Site for MEF2 Expressed in Muscle and Brain Reveals Tissue-specific Sequence Constraints
  187. Regulation of Gax homeobox gene transcription by a combination of positive factors including myocyte-specific enhancer factor 2.
  188. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation.
  189. A new bipartite DNA-binding domain: cooperative interaction between the cut repeat and homeo domain of the cut homeo proteins.
  190. hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors.
  191. GLUCOSE 1, 6-BISPHOSPHATE AND FRUCTOSE 2, 6-BISPHOSPHATE IN MUSCLE FROM HEALTHY HUMANS AND CHRONIC ALCOHOLIC PATIENTS
  192. Identification of guanine and adenine nucleotides as activators of glucose-1,6-bisphosphatase activity from rat skeletal muscle
  193. Regulation of muscle phosphofructokinase by physiological concentrations of bisphosphorylated hexoses: Effect of alkalinization
  194. Effect of denervation on the distribution and developmental transition of phosphoglycerate mutase and creatine phosphokinase isozymes in rat muscles of different fiber-type composition
  195. Distribution and developmental transition of phosphoglycerate mutase and creatine phosphokinase isozymes in rat muscles of different fiber-type composition
  196. Allosteric inhibition of Dictyostelium discoideum fructose‐1,6‐bisphosphatase by fructose 2,6‐bisphosphate
  197. Activation of muscle phosphofructokinase by α-glucose 1,6-bisphosphate and fructose 2,6-bisphosphate is differently affected by other allosteric effectors and by pH